Tag: health
-
Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis
Novartis reported positive Phase 3 results for remibrutinib in both REMODEL-1 and REMODEL-2, with significant reductions in annualized relapse rate versus teriflunomide and no liver safety signal reported across the two studies.
-
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining a precision autoantibody-degradation platform and multiple immunology programs.
-
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.
-
How Lisraya Targets Dermatomyositis Through TYK2/JAK1 Inhibition
Lisraya (brepocitinib) inhibits TYK2 and JAK1, reducing STAT-dependent inflammatory signaling involved in skin and muscle inflammation in dermatomyositis.
-
How Rusfertide Controls Red Blood Cell Overproduction in Polycythemia Vera
Rusfertide mimics hepcidin to reduce ferroportin-mediated iron export, restricting the iron available for excessive red blood cell production in polycythemia vera.
-
Eli Lilly Wins FDA Approval for Mounjaro to Reduce Cardiovascular Risk
The FDA approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
-
Why pTau217 Can Reveal Alzheimer’s Pathology from Blood
pTau217 rises with Alzheimer’s-related brain pathology and can be measured in blood, enabling a simpler approach to amyloid assessment.
-
How Daraxonrasib Blocks Active RAS Across Multiple Mutations
Daraxonrasib forms a cyclophilin A-dependent tri-complex with active RAS, blocking downstream signaling across multiple RAS variants.
-
Moderna Wins FDA Approval for the First mRNA Flu Vaccine
FDA approval of Moderna’s mFlusiva marks the first U.S. approval of an mRNA flu vaccine and expands the platform beyond COVID-19.
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.